Pre-Open Stock Movers 05/21: (AMPE) (CTP) (BLUE) Higher; (WAVX) (LL) (NTAP) Lower (more...)

May 21, 2015 9:32 AM EDT

Ampio Pharmaceuticals, Inc. (NYSE: AMPE) 40.9% HIGHER; announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).

CTPartners Executive Search (NYSE: CTP) 35.8% HIGHER; announced that pursuant to its previously announced strategic alternatives process, the Company has received a non-binding indication of interest from DHR International Inc. (DHR International) to acquire the Company. The special committee of the Companys board of directors, which was formed to evaluate the Companys strategic alternatives, has agreed to negotiate exclusively with DHR for a limited period of time in an effort to reach a definitive agreement. Pricing and other terms have not been disclosed, but the indicated preliminary price range set forth in the indication of interest submitted by DHR International is below the $7.00 per share DHR previously proposed to pay in a February 5, 2015 letter to the CTP board of directors. All terms of any definitive agreement, including price, will be subject to completion of confirmatory due diligence to the satisfaction of DHR and negotiation between the parties. There is no assurance that the parties will enter into a binding acquisition agreement consistent with the indication of interest, or on any other terms.

Wave Systems (NASDAQ: WAVX) 22.9% LOWER; announced the pricing of a $4.7 million underwritten public offering of 7.3 million units. Each unit consists of one share of Class A common stock and a warrant to purchase 0.5 shares of Class A common stock, at a public offering price of $0.65 per unit.

Lumber Liquidators (NYSE: LL) 16.5% LOWER; announced that Robert M. Lynch unexpectedly notified the Company of his resignation as the Company's President and Chief Executive Officer. The Company intends to commence a national search for Mr. Lynch's replacement. In the interim, Thomas D. Sullivan, the Company's Founder, will serve as the acting chief executive officer of the Company.

Xunlei (NASDAQ: XNET) 16% LOWER; reported Q1 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $30.2 million versus the consensus estimate of $39.7 million. Guidance for Second Quarter 2015 For the second quarter of 2015, Xunlei estimates total revenues from continuing operations to be between US$25 million to US$29 million, the midpoint of the range representing a year over year decrease of 18.9% and a quarter-over-quarter decline of 10.6%, respectively. This estimate represents management's preliminary view as of the date of this release, which is subject to change and change could be material. *** The Street sees Q2 revenue of $43.6 million.

Calithera Biosciences (NASDAQ: CALA) 15.2% HIGHER; announced that data from its lead, first-in-class program CB-839 will be presented at the 20th Congress of the European Hematology Association (EHA) June 11-15, 2015, in Vienna, Austria. These preliminary data demonstrate the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with acute leukemia. "We are very encouraged by these early clinical data," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "While the primary objectives of this study are to determine the safety and tolerability of CB-839, we were also able to demonstrate promising clinical activity including a complete response in the bone marrow, with incomplete recovery of peripheral counts (CRi) in one patient."

bluebird bio, Inc. (Nasdaq: BLUE) 12.2% HIGHER; announced that data from the ongoing Phase 1/2 HGB-205 study of LentiGlobin BB305 Drug Product will be presented in an oral presentation on June 13, 2015 at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria. The early data included in our abstract provide further validation for our approach and important insights into the safety and mechanism of action of LentiGlobin in both beta-thalassemia and sickle cell disease, said David Davidson, chief medical officer, bluebird bio. As noted in the abstract, we are pleased to report that the two patients with beta-thalassemia major, on whom we first reported last year at EHA, remained transfusion independent at 14 and 11 months post-transplant. In addition, it is very encouraging that the patient with sickle cell disease is increasing production of HbAT87Q, which has anti-sickling properties, and has not had a post-treatment hospitalization for a sickle cell disease-related event. At EHA we will present further follow up data on all three subjects.

NetApp (NASDAQ: NTAP) 9.7% LOWER; reported Q4 EPS of $0.65, $0.07 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $1.54 billion versus the consensus estimate of $1.59 billion. NetApp sees Q1 2016 EPS of $0.20-$0.25, versus the consensus of $0.60. NetApp sees Q1 2016 revenue of $1.275-1.375 billion, versus the consensus of $1.46 billion.

Quality Systems (NASDAQ: QSII) 9.5% HIGHER; reported Q4 EPS of $0.21, $0.06 better than the analyst estimate of $0.15. Revenue for the quarter came in at $128.4 million versus the consensus estimate of $126.23 million.

IsoRay, Inc. (NYSE: ISR) 8.8% HIGHER; continues yesterday's major run.

Best Buy (NYSE: BBY) 7.5% HIGHER; reported Q1 EPS of $0.37, $0.08 better than the analyst estimate of $0.29. Revenue for the quarter came in at $8.56 billion versus the consensus estimate of $8.46 billion.

Kirkland's (NASDAQ: KIRK) 7% HIGHER; reported Q1 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $118.3 million versus the consensus estimate of $117.68 million.

Trina Solar (NYSE: TSL) 7% HIGHER; reported Q1 EPS of $0.16, $0.07 better than the analyst estimate of $0.09. Revenue for the quarter came in at $558.1 million versus the consensus estimate of $509.35 million.

500.com Ltd (NYSE: WBAI) 6.2% LOWER; Deutsche Bank downgraded from Hold to Sell with a price target of $13.80 (from $11.00).

8x8, Inc. (NASDAQ: EGHT) 5.8% HIGHER; reported Q4 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $43.5 million versus the consensus estimate of $43.13 million. 8x8, Inc. sees FY2016 revenue of $193-197 million, versus the consensus of $193.84 million. It sees non-GAAP net income as a percentage of revenue in the 6% - 9% range.

Sarepta Therapeutic (NASDAQ: SRPT) 5.8% LOWER; BofA/Merrill Lynch downgraded from Buy to Neutral with a price target of $28.00 (from $20.00)

Bruker Corporation (NASDAQ: BRKR) 4.9% LOWER; announced that on May 19, 2015, Mr. Charles F. Wagner, Jr., Executive Vice President and the Chief Financial Officer (CFO) of Bruker since July 2012, submitted his resignation, effective June 12, 2015, in order to pursue other interests. Mr. Wagner has informed the Company that he has accepted a position as Chief Financial Officer of Ortho-Clinical Diagnostics, Inc., and will commence service in that position in late June 2015. Mr. Wagners resignation is not the result of any dispute or disagreement with the Company or any matter relating to the Companys accounting practices or financial statements.

OXiGENE (NASDAQ: OXGN) 4.9% LOWER; filed a $75 million mixed shelf. The shelf allows for the sale of common stock, preferred stock, debt, warrants, rights, purchase contracts, and units.

salesforce.com (NYSE: CRM) 4.8% HIGHER; reported Q1 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $1.51 billion versus the consensus estimate of $1.5 billion. salesforce.com sees Q2 2016 EPS of $0.17 - $0.18, versus the consensus of $0.17. salesforce.com sees Q2 2016 revenue of $1.59 - $1.60 billion, versus the consensus of $1.59 billion. salesforce.com sees FY2016 EPS of $0.69 - $0.71, versus the consensus of $0.69. salesforce.com sees FY2016 revenue of $6.52 - $6.55 billion, versus the consensus of $6.51 billion.

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) 4.8% LOWER; announced today the pricing of its underwritten registered public offering of 2,750,000 shares of its common stock at a price to the public of $17.75 per share. Closing of the offering is expected to occur on May 27, 2015, subject to customary closing conditions. Dicerna also granted the underwriters a 30-day option to purchase up to 412,500 additional shares of common stock.

Advance Auto Parts (NYSE: AAP) 3.6% LOWER; reported Q1 EPS of $2.39, $0.11 worse than the analyst estimate of $2.50. Revenue for the quarter came in at $3.04 billion versus the consensus estimate of $3.05 billion. Comps rose 0.7 percent. Advance Auto Parts sees FY2015 EPS of $8.10 - $8.30, versus the consensus of $8.51.

TeleNav (NASDAQ: TNAV) 3.5% HIGHER; Northland Capital Markets initiates coverage with a Outperform rating and a price target of $15.00.

Williams-Sonoma (NYSE: WSM) 3.4% HIGHER; reported Q1 EPS of $0.48, $0.04 better than the analyst estimate of $0.44. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.01 billion. The company reported comparable brand revenue growth of 4.6%. Williams-Sonoma sees Q2 2015 EPS of $0.53-$0.57, versus the consensus of $0.59. Williams-Sonoma sees Q2 2015 revenue of $1.085-1.105 billion, versus the consensus of $1.1 billion. The company comparable brand revenue growth of 4-6%. Williams-Sonoma sees FY2015 EPS of $3.35-$3.45, versus the consensus of $3.46. Williams-Sonoma sees FY2015 revenue of $4.95-5.02 billion, versus the consensus of $4.99 billion.The company comparable brand revenue growth 4-6%.

Agenus Inc. (NASDAQ: AGEN) 3% LOWER; announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per share

Stratasys Inc. (NASDAQ: SSYS) 2.8% HIGHER; Oppenheimer upgraded from Perform to Outperform with a price target of $50.00.

Fate Therapeutics (NASDAQ: FATE) 2.6% LOWER; announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $5.00 per share, before underwriting discounts, for an aggregate offering of $30 million.

Youku Tudou (NYSE: YOKU) 2% HIGHER; reported Q1 EPS of (RMB2.49). Revenue for the quarter came in at RMB1.14 billion versus RMB1.06 billion last year. Youku Tudou sees Q2 2015 revenue of RMB1.47-1.52 billion.

Synopsys (NASDAQ: SNPS) 1.4% LOWER; reported Q2 EPS of $0.68, $0.05 better than the analyst estimate of $0.63. Revenue for the quarter came in at $557.2 million versus the consensus estimate of $546.46 million. Synopsys sees Q3 2015 EPS of $0.58-$0.60, versus the consensus of $0.66. Synopsys sees Q3 2015 revenue of $550-560 million, versus the consensus of $557.4 million. Synopsys sees FY2015 EPS of $2.76-$2.81, versus the consensus of $2.78. Synopsys sees FY2015 revenue of $2.21-2.235 billion, versus the consensus of $2.22 billion.

L Brands (NYSE: LB) 1.3% LOWER; reported Q1 EPS of $0.61, $0.01 better than the analyst estimate of $0.60. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.54 billion. Comparable store sales for the first quarter ended May 2, 2015, increased 5 percent. L Brands sees FY2015 EPS of $3.50-$3.70, versus prior guidance of $3.45-$3.65 and the consensus of $3.75. L Brands sees Q2 2015 EPS of $0.60-$0.65, versus the consensus of $0.69.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Deutsche Bank, Pre-Open Losers, Pre-Open Winners, Definitive Agreement